...
首页> 外文期刊>Vaccine >Influenza bivalent vaccine comprising recombinant H3 hemagglutinin (HA) and H1 HA containing replaced H3 hemagglutinin transmembrane domain exhibited improved heterosubtypic protection immunity in mice
【24h】

Influenza bivalent vaccine comprising recombinant H3 hemagglutinin (HA) and H1 HA containing replaced H3 hemagglutinin transmembrane domain exhibited improved heterosubtypic protection immunity in mice

机译:包含重组H3血凝素(HA)和含有H3血凝素跨膜结构域的H1 HA的流感二价疫苗在小鼠中表现出改善的异型保护免疫

获取原文
获取原文并翻译 | 示例
           

摘要

Influenza caused by infection of influenza viruses is still a leading cause of morbidity and mortality in human. Vaccination is the main defense against influenza virus, but current influenza trivalent or quatrivalent vaccines (TIV/QIV) would lose their effectiveness when vaccine strains are mismatched with circulating strains. Our early study showed that recombinant influenza Hx-TM HA proteins containing H3 HA transmembrane domain(TM) had improved immunogenicity and heterosubtypic protection over corresponding wild-type Hx-WT HA proteins. In present study, bivalent vaccines containing H3-WT+Hx-TM were investigated for their immune responses and heterosubtypic protection immunities. The data showed that the bivalent vaccines containing H3-WT and H5-TM or H1-TM had improved immune responses and heterosubtypic protection over the bivalent vaccines containing H3-WT and H5-WT or H1-WT respectively. These results demonstrated that the improved immune responses and heterosubtypic protection of Hx-TM HA proteins could be translated into bivalent vaccines, suggesting a feasible strategy of improving the immune responses and heterosubtypic protection of influenza multivalent vaccines such as TIV and QIV. (C) 2015 Elsevier Ltd. All rights reserved.
机译:由流感病毒感染引起的流感仍然是人类发病和死亡的主要原因。疫苗接种是抵抗流感病毒的主要防御手段,但是当疫苗株与循环株不匹配时,当前的三价或四价流感疫苗(TIV / QIV)会失去效力。我们的早期研究表明,与相应的野生型Hx-WT HA蛋白相比,含有H3 HA跨膜结构域(TM)的重组Hx-TM HA蛋白具有更高的免疫原性和异型保护作用。在本研究中,研究了含有H3-WT + Hx-TM的二价疫苗的免疫应答和异型保护免疫。数据显示,与分别含有H3-WT和H5-WT或H1-WT的二价疫苗相比,含有H3-WT和H5-TM或H1-TM的二价疫苗具有更好的免疫反应和异型保护。这些结果表明,可以将改进的Hx-TM HA蛋白的免疫应答和异型保护转化为二价疫苗,从而提出了提高TIV和QIV等流感多价疫苗的免疫应答和异型保护的可行策略。 (C)2015 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号